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Abstract. Genetic skeletal diseases (GSDs) are an extremely 
diverse and complex group of rare genetic diseases that 
primarily affect the development and homeostasis of the 
osseous skeleton. There are more than 450 unique and well-
characterised phenotypes that range in severity from relatively 
mild to severe and lethal forms. Although individually rare, 
as a group of related genetic diseases, GSDs have an overall 
prevalence of at least 1 per 4,000 children. Qualitative defects 
in cartilage structural proteins result in a broad spectrum of 
both recessive and dominant GSDs. This review focused 
on a disease spectrum resulting from mutations in the non-
collagenous glycoproteins, cartilage oligomeric matrix protein 
(COMP) and matrilin-3, which together cause a continuum 
of phenotypes that are amongst the most common auto-
somal dominant GSDs. Pseudoachondroplasia (PSACH) and 
autosomal dominant multiple epiphyseal dysplasia (MED) 
comprise a disease spectrum characterised by varying degrees 
of disproportionate short stature, joint pain and stiffness and 
early-onset osteoarthritis. Over the past decade, the generation 
and deep phenotyping of a range of genetic mouse models 
of the PSACH and MED disease spectrum has allowed the 
disease mechanisms to be characterised in detail. Moreover, 
the generation of novel phenocopies to model specific disease 
mechanisms has confirmed the importance of endoplasmic 
reticulum (ER) stress and reduced chondrocyte proliferation 
as key modulators of growth plate dysplasia and reduced 
bone growth. Finally, new insight into related musculoskeletal 
complications (such as myopathy and tendinopathy) has also 
been gained through the in-depth analysis of targeted mouse 
models of the PSACH-MED disease spectrum.
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1. Skeletal dysplasias resulting from mutations in cartilage 
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Qualitative (i.e., dominant-negative or antimorphic mutations) 
defects in cartilage structural proteins result in a diverse 
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range of both recessive and dominant genetic skeletal dyspla-
sias (Table Ι). These structural proteins include cartilage 
collagens (types II, IX and XI), proteoglycans (aggrecan) and 
glycoproteins [cartilage oligomeric matrix protein (COMP) 
and matrilin-3 (MATN3)] and many of the mutations are 
predicted to affect the folding and/or function of these impor-
tant molecules. This review specifically concentrates on those 
diseases resulting from mutations in the non-collagenous 
glycoproteins, COMP and matrilin-3, which together cause a 
continuum of phenotypes that are amongst the most common 
autosomal dominant skeletal dysplasias.
The pseudoachondroplasia (PSACH) and multiple epiphyseal 
dysplasia (MED) disease spectrum: the generation and study 
of genetic mouse models. Originally believed to be different but 
clinically related phenotypes, it was gene and mutation identi-
fication in the 1990s that demonstrated that PSACH and some 
forms of MED were allelic diseases resulting from mutations 
in COMP (1). However, MED is genetically heterogeneous and 
autosomal dominant forms can also result from mutations in the 
genes encoding matrilin-3 and type IX collagen (2) (Table Ι).
Despite the first mutations being identified in COMP, 
MATN3 and the type IX collagen genes in the six years 
between 1995 and 2001 (Table Ι), very little progress has been 
made in understanding disease mechanisms despite numerous 
cell culture studies (reviewed in ref. 3). A lack of relevant patho-
logical tissues (such as cartilage growth plate), and the obvious 
limitations of cell culture models to study long bone growth, 
meant that only small incremental increases in knowledge were 
possible.
Over the past eight years, however, a number of different 
genetic approaches have been used to generate mouse models 
of PSACH-MED that recapitulate the various phenotypes 
and allow disease mechanisms to be studied in detail 
in vivo (Table ΙΙ). Moreover, the generation of novel pheno-
copies to model specific disease mechanisms have confirmed 
the importance of endoplasmic reticulum (ER) stress and 
chondrocyte proliferation as key modulators of growth plate 
dysplasia. Finally, new insight into related musculoskeletal 
complications (such as myopathy and tendinopathy), which may 
be of clinical utility, has also been gained through the in-depth 
analysis of targeted mouse models of the PSACH-MED disease 
spectrum.
2. Knock-in mouse models provide new insight into disease 
mechanisms
The application of homologous recombination and Cre-lox 
technology has allowed the generation of a series of mouse lines 
that genetically modelled phenotypes within the PSACH-MED 
disease spectrum, thereby allowing key pathological findings 
to be described and disease mechanisms to be studied in 
detail (Tables II and III).
In the first instance, an allelic series of PSACH models were 
generated representing the two major classes of COMP muta-
tions: the type III repeat (T3) region and the carboxyl-terminal 
domain (CTD) (2,4). Type III repeat region mutations account 
for approximately 85% of all COMP-related PSACH-MED, 
whereas CTD mutations represent 15% of cases (2). The muta-
tions that were selected to represent these two different classes 
were the common in-frame deletion of an aspartic acid residue 
from the C-type motif of repeat T37 (p.Asp469del), which 
accounts for 30% of all PSACH, and the recurrent p.Thr585Met 
missense mutation in the CTD (2,4). The p.Thr585Met muta-
tion has been reported in four different studies and results in a 
phenotypic spectrum ranging from MED to mild PSACH (4). 
Previous studies using cell models consistently demonstrated 
the retention of mutant Asp469del COMP in the ER (3). By 
contrast, p.Thr585Met, along with several other CTD muta-
tions, was efficiently secreted into the culture media of various 
cell models (5,6). These early cell model studies have suggested 
different disease mechanisms between these two classes of 
mutations that justified validation and in-depth analysis using 
relevant mouse models.
The p.Thr585Met (CompT585M) model of mild PSACH/severe 
MED. Individuals with p.Thr585Met [and several other CTD 
mutations (4)] often present with a mild form of PSACH and 
this was reflected in the CompT585M mouse model which showed 
only a 5% reduction in bone length at 9 weeks of age (7). This 
is consistent with previous family studies, which demonstrated 
that individuals with the Thr585Met mutation may have average 
stature, despite having significant epiphyseal and metaphyseal 
changes in the large joints (8).
Immunohistochemistry and electron microscopy confirmed 
a lack of mutant protein retention in the ER (Figs. 1 and 2), 
which is consistent with previous cell culture studies (5,6). 
However, there were severe disruptions to the morphology of 
the growth plate and to the size, shape and arrangement of indi-
vidual chondrocytes and chondrons (7). The composition of the 
growth plate extracellular matrix (ECM) was also disrupted 
with changes to the localisation of several ECM proteins and 
the under-sulfation of proteoglycans (7). Proteomic inter-
rogation confirmed changes to the extractability of several 
ECM proteins, including collagens [α1(XIV), α1(IX), α1(XI), 
α1(XII) and α6(VI)], laminin β2 and fibronectin (9). Finally, 
there was a significant reduction in chondrocyte proliferation 
that was accompanied by increased and spatially dysregulated 
apoptosis (7) (Table ΙΙΙ).
The p.Asp469del (CompD469del) model of typical severe PSACH. 
p.Asp469del is the most common COMP mutation and invari-
ably results in typically severe PSACH (4,5). Numerous cell 
culture studies have been undertaken on this archetypal 
mutation, which have consistently shown that p.Asp469del 
results in the retention of mutant COMP protein within the 
rough ER (rER) of cells, along with matrilin-3 and collagen 
type IX (10,11). Furthermore, cartilage samples from PSACH 
patients appear to have a disorganised ECM and there is an 
increase in cell death in vivo (12) that can be recapitulated 
in vitro by several different cell culture models (13,14).
CompD469del mice were normal at birth, but grew slower 
than their wild-type littermates and developed a progres-
sive short-limb dwarfism, which was characterised by a 
5-6% reduction in final tibia and femur lengths. Moreover, the 
mutant mice developed a hip dysplasia that was characterised 
by an increase in the angle of deflection from the vertical of the 
tuberosity of the ischium (15). The reductions in the final bone 
lengths of CompD469del mice were less than would be expected 
for a phenotypically exact model of typical severe PSACH and 
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may be best explained by the mixed genetic background of the 
mutant mouse strain.
Notwithstanding the relatively mild reduction in final bone 
lengths of CompD469del mice, there was significant growth 
plate pathology that was illustrative of the hallmarks of 
PSACH (15) (Table ΙΙΙ). In particular, chondrocyte columns 
were reduced in number and poorly organised in the growth 
plates of CompD469del mice, whilst mutant COMP was retained 
within the ER of chondrocytes at all stages of differentia-
tion (15) (Fig. 1). The composition and appearance of the ECM 
was disrupted, with changes to the localisation of several ECM 
proteins, including the co-retention of matrilin-3 and type IX 
collagen (15). Proteomic interrogation confirmed changes to 
the extractability of several ECM proteins, including throm-
bospondin-3 and -4, several collagens [α1(XIV), α1(IX) and 
α1(VI)], tenascin-C and -X and epiphycan (9). Most notice-
ably, chondrocyte proliferation was significantly reduced 
and apoptosis was greatly increased in the proliferative zone 
Table I. Human genetic skeletal diseases result from qualitative (anti-morphic) defects in cartilage structural proteins.
Gene Protein Disease(s) Genetic loci Domain Refs.
COMP COMP Pseudoachondroplasia (AD) PSACH T3-7 repeats (4,45)
  Multiple epiphyseal dysplasia (AD) EDM1 C-terminal domain 
MATN3 Matrilin-3 Multiple epiphyseal dysplasia (AD) EDM5 vWFA  (18)
COL9A1 Type IX collagen Multiple epiphyseal dysplasia (AD) EDM6 COL3 domain (46-48)
COL9A2   EDM2
COL9A3   EDM3
COL2A1 Type II collagen Diverse range of AD and  Various Triple helical (49)
  AR phenotypes collectively known   region and
  as type II collagenopathies   C-propeptide
COL11A1 Type XI collagen Diverse range of AD and Various  (50)
COL11A2  AR phenotypes collectively known
  as type XI collagenopathies
COL10A1 Type X collagen Metaphyseal chondrodysplasia,  MCDS Carboxyl-terminal (51)
  type Schmid (AD)  non-collagenous
    domain (NC1)
ACAN Aggrecan Spondyloepimetaphyseal dyslasia (AR) SEMD G3 C-type (52-54)
  Osteochondritis dissecans (AD)  OCD lectin domain
  Short stature, accelerated bone
  maturation (AD)
COMP, cartilage oligomeric matrix protein; PSACH, pseudoachondroplasia; AD, autosomal dominant; AR, autosomal recessive.
Table II. Mouse models of the PSACH-MED disease spectrum and novel phenocopies to model ER stress in the cartilage 
growth plate.
Disease Gene Mutation Approach taken Promoter Refs.
PSACH COMP D469del Transgenic (rat COMP cDNA) Col2a1 (20)
PSACH COMP D469del Transgenic (human COMP gene) Native (3)
PSACH COMP D469del Transgenic (human COMP cDNA) Col2a1 (3)
PSACH COMP D469del Transgenic inducible overexpression Col2a1 and tetracycline  (21,22,44)
   (human COMP cDNA) responsive element
PSACH COMP D469del Knock-in Native (9,15,42)
PSACH-MED COMP T585M Knock-in Native (7,9,38,41)
MED MATN3 V194D Knock-in Native (9,19,23,42)
Chondrodysplasia TG Rdw (G2320R) Transgenic phenocopy Col2a1 (31)
Chondrodysplasia TG Cog (L2293P) Transgenic phenocopy Col2a1 (55)
ER, endoplasmic reticulum; COMP, cartilage oligomeric matrix protein; PSACH, pseudoachondroplasia; MED, multiple epiphyseal dysplasia.
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and spatially dysregulated throughout the entire growth 
plate (15) (Table ΙΙΙ).
The p.Val194Asp (Matn3V194D) model of moderate MED. 
Missense mutations and small in-frame deletions in the 
von Willebrand Factor A (vWFA) domain of matrilin-3 cause 
moderate to severe forms of MED (2). The various missense 
mutations are distributed between the β-sheet (~85%) and 
α-helical (~15%) regions of the vWFA domain. Mutations in 
the β-sheet regions primarily disrupt the folding of the vWFA 
domain, resulting in the retention of mutant protein in the 
ER of cells (16). By contrast, some α-helical mutations allow 
the correct folding and secretion of mutant matrilin-3 (17); 
however, there are exceptions to these generalisations. The 
MATN3 mutation (p.Val.194Asp) selected for mouse model 
generation was the first EDM5 mutation to be identified and is 
an archetypal example (18).
Matn3V194D mice were normal at birth but developed short-
limbed dwarfism that was characterised by a final reduction in 
tibia length of 12-13% (19). There was a significant retention 
of mutant matrilin-3 in the growth plate chondrocytes, which 
were abnormal in shape and resulted in poorly organised chon-
drons and chondrocyte columns (Figs. 1 and 2). Chondrocyte 
proliferation was significantly reduced and whilst there was 
no overall increase in apoptosis it was noticeably dysregulated 
with increased cell death occurring throughout the entire 
hypertrophic zone (19) (Table III). Changes to the appearance 
of the cartilage ECM may be partly attributable to differences 
Figure 1. Organization of the growth plate in mutant mice is disrupted by 3 weeks of age and shows marked hypocellularity along with the retention and/or 
mislocalisation of cartilage structural proteins. Representative immunohistochemistry (IHC) of the growth plates from 3 week-old wild-type and mutant mice 
showing disruption to chondrocyte columns in mice homozygous for the Comp p.Thr585Met (CompT585M), Comp p.D469del (CompD469del) and Matn3 Val194Asp 
(Matn3V194D) mutations. IHC using COMP (wild-type, CompT585M and CompD469del) and matrilin-3 (Matn3V194D) antibodies revealed less staining in the extracellular 
matrix (ECM) between the proliferating columns in the growth plates of mice carrying all three mutations. Furthermore, there was intracellular staining for 
mutant COMP and matrilin-3 in chondrocytes from the CompD469del and Matn3V194D mice, respectively.
Table III. Key pathological and quantitative measures of disease severity in various knock-in mouse models of PSACH-MED 
and novel ER stress phenocopies.
   Cell
 Final reduction in bone length proliferation Apoptosis
 Age at ------------------------------------------------------------------- ----------------------- --------------------------- Protein ER Stress
Model onset 3 weeks 6 weeks 9 weeks 3 weeks 3 weeks retention stress pathway
CompD469del ~6 weeks  No ↓ 6%   ↓ 5% ↓ 17% ↑ 90-fold (Pz) Yes Yes Novel
  differences    ↑ 5-fold (Hz)   (APR/EOR)
CompT585M ~9 weeks No No   ↓ 5% ↓ 24% ↑ 3-fold (Rz) Slight Mild Mild UPR
  differences differences   ↑ 12-fold (Pz)
	 	 	 	 	 	 ↑ 3-fold (Hz)
Matn3V194D ~2 weeks ↓ 12% ↓ 13% ↓ 12% ↑ 16% Spatially Yes Yes UPR
      dysregulated
Col2-TgRdw At birth   ↓ 8%   ↓ 5%   ↓ 5% ↑ 21% No differences Yes Yes UPR
Col2-Tgcog ~3 weeks   ↓ 7%   ↓ 4%   ↓ 4% ↑ 12% No differences Yes Yes Novel
EOR, ER overload response; ER, endoplasmic reticulum; APR, aggregated protein response; UPR, unfolded protein response; Pz, proliferative 
zone; Hz, hypertrophic zone; Rz, resting zone; PSACH, pseudoachondroplasia; MED, multiple epiphyseal dysplasia.
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in the extractability of various collagens [α1(XIV) and α3(VI)], 
osteomodulin, biglycan, tenascin-C and epiphycan (9).
3. Transgenic approaches for generating mouse models
Several transgenic approaches have also been used to generate 
mouse models of the common PSACH mutation, which do not 
rely on the targeted integration of a single copy of the mutant 
allele (Table II).
Standard transgenic approaches. In the first example, a 
transgenic mouse model was generated by Schmitz et al, in 
which rat Asp469del COMP cDNA expression was achieved 
through the Col2a1 promoter (20). Mutant COMP was over-
expressed by ~40% and transgenic mutant male mice were up 
to 8% shorter than transgenic wild-type mice at 6 months of 
age. In an attempt to exacerbate this relatively mild phenotype, 
the transgenic mutant mice were crossed onto a Comp-null line 
to ensure that only rat COMP Asp469del was expressed by 
chondrocytes. This cross resulted in a male-specific increase 
in disease severity that was characterised by a further decrease 
in body and femur lengths. Chondrocytes within the prolifera-
tive zone showed the retention of the transgenic mutant COMP, 
the levels of which were further increased on the Comp-null 
background (20). Moreover, there were abnormal changes to 
the morphology of the cartilage ECM, including the loss of 
proteoglycans and changes to the localisation of other ECM 
molecules, such as type VI collagen, aggrecan and matrilin-1. 
Finally, increased apoptosis was observed in combination with 
distinct areas of hypocellularity and these key pathological 
Figure 2. Chondrocytes have dilated cisternae of endoplasmic reticulum (ER) and the extracellular matrix (ECM) ultrastructure is altered in mutant growth 
plates. These representative images were taken from a complete TEM montage of a day 7 tibia growth plate (from resting to mineralisation zones) and show 
chondrons from the proliferative zone of mice homozygous for the Comp p.Thr585Met (CompT585M), Comp p.D469del (CompD469del) and Matn3 Val194Asp 
(Matn3V194D) mutations. Top panel, the ultrastructure of the interterritorial matrix at 1 week of age is altered in all three mutant growth plates and is characterised 
by more prominent appearing collagen fibrillar material. Scale bars, 1.2 µm (wild-type, CompD469del and Matn3V194D) or 1.4 µm (CompT585M). Middle and bottom 
panels, chondrocytes from CompD469del and Matn3V194D mice which show enlarged individual cisternae of ER compared to the wild-type mice in which the ER 
displays has the typical ribbon appearance. The CompT585M growth plate shows misaligned and abnormally shaped chondrocytes despite mutant T585M COMP 
being secreted.
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features are now recognised as hallmark descriptors of the 
PSACH growth plate in vivo (20).
Subsequently, Posey et al hypothesised that the overexpres-
sion of Asp469del COMP would best recapitulate the PSACH 
disease phenotype in a mouse model and therefore used the 
inducible overexpression of mutant Comp that was driven from 
the Col2a1 promoter (21). One reason for taking this approach 
was as a consequence of limited phenotypic and pathological 
effects observed in earlier PSACH transgenic mice models (3), 
which highlights the unpredictability of standard transgenic 
approaches for developing mouse models of human genetic 
skeletal diseases (GSDs) (Table II).
In the first model, a BAC clone containing human COMP 
and its native promoter was used to generate two founders 
(1 male and 1 female) of which only the female demonstrated 
a clinical phenotype and both founders died prematurely (3). 
In a second approach, Asp469del COMP expression from 
human cDNA was driven by a mouse Col2a1 promoter and 
enhancer. Genomic analysis demonstrated that 12-20 copies of 
the transgene had integrated into mouse chromosome 10. Tibia 
measurements confirmed a 6% reduction in final length and 
there was some disorganization of the growth plate, with fewer 
chondrocytes organised into columns of chondrons; however, 
in contrast to the study by Schmitz et al (20), no intracellular 
retention of mutant Asp469del COMP was observed in growth 
plate chondrocytes (3).
Bigenic inducible overexpression of mutant Comp Asp469del. 
The most recent transgenic approach involved the generation 
of bigenic mice in which the expression of Comp Asp469del 
was controlled by a tetracycline responsive element promoter, 
which was itself under the control of the tetracycline trans-
activator coding sequence with a Col2a1 promoter to ensure 
cartilage-specific expression (21). Whilst Col2a1-driven 
overexpression of Comp Asp469del was assumed to be robust, 
the levels of mutant Comp mRNA were only determined 
at E15 and shown to be 4- to 6-fold higher than endogenous 
Comp mRNA (21). Unfortunately, the relative levels of Comp 
Asp469del mRNA and protein were not determined at later 
time-points, thus limiting the interpretation of phenotypic and 
pathological readouts, particularly when these analyses were 
performed postnatally. Nevertheless, key pathological features 
such as mutant COMP retention, growth plate dysplasia and 
marginally increased chondrocyte apoptosis were identified 
in this mouse model (21). Subsequent developmental analysis 
of this mouse model (22) confirmed growth plate dysplasia 
by 3 weeks of age that was characterised by disorganization, 
reduced thickness and distinct areas of hypocellularity. Mutant 
Asp469del COMP retention was shown to be progressive until 
2 weeks of age. Analysis of chondrocyte death by terminal 
deoxynucleotidyltransferase-mediated dUTP nick-end label-
ling (TUNEL) confirmed that abnormally increased apoptosis 
was occurring in the hypertrophic zone by 2 weeks of age, and 
increased further with age (~3-4-fold); however, the precise 
localisation of increased apoptosis within the different growth 
plate zones was not determined. Long bone growth was signifi-
cantly reduced by 12% in the tibia; however, skull and snout 
lengths were also shown to be smaller than wild-type controls, 
indicating that intramembraneous ossification was also 
disrupted by the transgenic overexpression of mutant COMP, 
which is not consistent with other mouse models or individuals 
with PSACH. Moreover, the pathophysiological relevance 
of Comp Asp469del overexpression is not known and whilst 
strong phenotypic effects were observed, the genetic pathways 
that are induced by this transgenic approach may not neces-
sarily be representative of the human disease.
4. Activation of canonical and/or novel ER stress pathways 
is genotype-specific
The expression of CompD469del and Matn3V194D results in ER 
retention of the relevant mutant proteins and the co-retention of 
interacting partners that ultimately results in ER stress (15,19); 
however, the downstream stress pathways that are activated are 
genotype-specific.
For example, the expression of Matn3V194D induces the activa-
tion of the canonical unfolded protein response (UPR), which is 
characterised by the upregulation of binding immunoglobulin 
protein (BiP) (a sentinel marker of UPR) and a broad range of 
chaperones, foldases and protein disulphide isomerases (23). 
Moreover, the downstream splicing of X-box binding protein 1 
(Xbp1) in Matn3V194D chondrocytes (and also in cell models) is 
symbolic of classical UPR; however, this prolonged ER stress 
does not result in a C/EBP-homologous protein (CHOP)-mediated 
increase in apoptosis (23) (and our unpublished observations).
In contrast to mutant matrilin-3, the ER retention of 
CompD469del does not induce a canonical UPR, but a novel form 
of ER stress that is characterised by changes in the expression 
of groups of genes implicated in oxidative stress, cell cycle 
regulation and apoptosis (15). Similar UPR-independent path-
ways, such as the ER overload response (EOR), appear to be 
associated with the aggregation of mutant proteins in the ER 
that eventually induce toxic gain-of-function (24). This has been 
noted with serpinopathies in which the aggregation of insoluble 
misfolded α1-antitrypsin triggers an alternative ER stress 
response that is independent of the UPR and involves the activa-
tion of nuclear factor-κB (NF-κB) signalling (25). Moreover, it 
has been proposed that an aggregating protein response (APR) 
is activated by glycine substitutions in the triple helical regions 
of type I collagen that also do not induce canonical UPR (26,27).
Our own studies have identified differences in the molecular 
organization of the mutant COMP and matrilin-3 proteins that 
are retained in the ER of mouse chondrocytes and cell culture 
models (9,28). Mutant matrilin-3 forms non-native disulphide 
bonded aggregates, due to a delay in the folding of the single 
vWFA domain, which may render it inaccessible to degrada-
tion. By contrast, mutant D469del COMP does not appear to 
aggregate and is retained in the ER in its apparent native state 
of either tetramers or pentamers (9). This difference in the 
molecular organization of mutant protein aggregates may play 
a role in determining which ER stress pathways are activated.
These unexpected findings demonstrate that ER stress, as a 
result of mutant protein misfolding, and the genetic pathways 
that are activated in an attempt to restore ER homeostasis, are 
likely to be more diverse in mouse models and human genetic 
diseases than in the more commonly studied chemically-
induced ER stress experimental systems (29). However, despite 
the downstream activation of several potential pathways, such 
as UPR, APR and/or EOR, a common consequence appears to 
be the reduction in chondrocyte proliferation (Table III).
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  35:  1483-1492,  2015 1489
5. Common genetic pathways identified in the different 
mouse models of Asp469del COMP pseudoachondroplasia
Despite differences in the relative severity of growth plate 
dysplasia, chondrocyte cell death and long bone growth between 
the different Comp Asp469del mouse models (Table II), tran-
scriptomic profiling has nevertheless implicated several genetic 
pathways in common (15,22).
The microarray analysis of mRNAs isolated from chon-
drocytes of the CompD469del knock-in mouse model showed a 
complex disease profile with expression changes in groups of 
genes implicated in oxidative stress, cell cycle regulation and 
apoptosis, which is consistent with the chondrocyte and growth 
plate pathology (15). Moreover, this study demonstrated that 
reduced cell proliferation and increased dysregulated chon-
drocyte apoptosis was associated with the downregulation of 
peroxiredoxin 2, which is a gene important for protecting cells 
against oxidative damage and also in regulating apoptosis (15). 
Similarly, transcriptomic analysis of mRNAs isolated from 
the chondrocytes of the bigenic transgenic mouse identified 
cell cycle regulation, inflammation, oxidative stress and DNA 
damage as the major classes of genes implicated in disease 
pathogenesis (22).
6. Missense mutations in matrilin-3 and COMP cause 
changes in the extractability of other cartilage proteins 
and influence ECM organization
Analysis of the cartilage proteome of Matn3V194D, CompD469del 
and CompT585M mice has identified differences in the extract-
ability of numerous structural ECM components relative to the 
controls (9). The extraction of type IX collagen [a fibril-asso-
ciated collagen with interrupted triple helices (FACIT)] was 
increased in CompD469del and CompT585M mice, which may alter 
the integrity of the II/IX/XI heterofibrillar collagen network. 
Other changes in the extractability of FACIT collagens 
were observed in Matn3V194D (i.e., the decreased extraction 
of collagen types XII and XIV), CompD469del (decrease in 
types IX and XIV) and CompT585M (decrease in types IX and 
XII, but increase in type XIV) cartilage, which further implied 
disruption to ECM organization as a consequence of Comp 
and Matn3 mutations that correlated with the observations 
of altered ECM morphology detected by electron micros-
copy (7,15,19) (Fig. 2).
In addition to these commonalities between mutant mouse 
models, discrete patterns of ECM protein extraction were also 
observed (9). Most notably, the extraction of tenascin X was 
greatly reduced from CompD469del cartilage; however, the func-
tional significance of this, and also the increases in tenascin C 
extractability observed in CompD469del and Matn3V194D mice, 
remains to be determined.
7. Novel phenocopies of chondrocyte-specific ER stress provide 
information regarding intracellular disease mechanisms and 
the influence of chondrocyte proliferation
Defining the relative contributions of intracellular disease 
mechanisms (ER stress) and extracellular defects (ECM disrup-
tion) to the initiation and progression of growth plate dysplasia 
is experimentally challenging. Therefore, to directly test the 
role of ER stress in growth plate dysplasia and reduced long 
bone growth, independent of disruptions to the cartilage ECM, 
a novel transgenic approach was taken. This approach was 
previously established and validated as an innovative tool to 
dissect disease mechanisms in metaphyseal chondrodysplasia 
type Schmid, which can be caused by missense mutations in 
the gene encoding type X collagen (30).
To delineate the relative influence of ER stress to the devel-
opment of chondrodysplasia, the expression of a G2320R mutant 
form of thyroglobulin (Rdw) was targeted primarily to resting 
and proliferating chondrocytes using the Col2a1 promoter (31). 
The expression and retention of this mutant exogenous protein 
in the rER of growth plate chondrocytes resulted in chronic 
cell stress and reduced bone growth, but without inducing any 
disruptions to the architecture and overall organization of the 
ECM. More significantly, however, decreased bone growth 
appeared to be the direct result of reduced chondrocyte prolif-
eration in the growth plates in transgenic mice.
8. Reduced chondrocyte proliferation is a shared cellular 
response to all forms of ER stress and defines a common 
denominator of PSACH-MED pathology
The pivotal role of ER stress in the initiation of growth plate 
dysplasia and abnormal bone growth was revealed through 
targeted knock-in mouse models and novel transgenic pheno-
copies (Table II). Whilst it has been previously suggested 
that increased and dysregulated chondrocyte apoptosis is the 
major cause of reduced bone growth in PSACH (22), our recent 
analysis of the TgRdw transgenic phenocopy has demonstrated 
that reduced chondrocyte proliferation alone is sufficient to 
cause a significant reduction in bone length in the absence of 
increased apoptosis or extensive disruption to cartilage ECM 
composition and assembly (31). We therefore hypothesise 
that modulating chondrocyte proliferation is likely to exert 
the greatest influence on long bone growth in PSACH-MED 
and this may represent an attractive target for therapy. Indeed, 
dysregulated cyclin D1 signaling during the G1 phase of the 
cell-cycle causes reduced chondrocyte proliferation in a mouse 
model of diastrophic dysplasia due to a p.A386V substitution in 
the eighth transmembrane domain of solute carrier family 26 
member 2 (Slc26a2) (32). Moreover, recent mouse model 
studies have demonstrated that long bone length can be restored 
in achondroplasia by targeting the mitogen-activated protein 
kinase (MAPK) pathway, which is activated by the tyrosine 
kinase receptor FGFR3 mutations in achondroplasia, and causes 
a disruption to normal chondrocyte differentiation (33). Finally, 
transgenic expression of mutant forms of type II collagen 
causes ER-stress induced chondrodysplasia (34,35), which can 
also defined by reduced chondrocyte proliferation and may be 
associated with disrupted cell polarity and the abnormal orga-
nization and morphology of the primary cilia (35).
9. Genetic background influences phenotypic severity in 
the CompT585M mouse model of PSACH-MED by impacting 
on chondrocyte proliferation and apoptosis
Several clinical genetic studies have demonstrated that there 
is considerable intra- and interfamilial variability in disease 
presentation in both PSACH and MED, which strongly points 
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to the existence of genetic modifiers of phenotypic severity. 
This is best highlighted by several MATN3 mutations, such 
as Arg121Trp, which are associated with marked interfamilial 
variability in the radiographic phenotype of patients (36). 
Patients carrying the T585M COMP mutation also show vari-
ability in final adult height (8).
In-bred mouse strains are a useful tool which can be 
used to study complex disease traits when the influence of a 
genetic modifier is suspected (37). Interestingly, crossing the 
CompT585M knock-in mice (originally on a mixed genetic back-
ground) onto a C57BL6/J inbred background has been shown 
to increase the severity of the phenotype by further disrupting 
chondrocyte proliferation, apoptosis and matrix deposi-
tion (38). Moreover, mutant COMP was retained inside the 
rER of chondrocytes, which was a feature not observed in the 
original mouse model (7). Dixon and Dixon (37) demonstrated 
a similar phenotypic variability in their model of craniofacial 
abnormalities in Treacher Collins Syndrome that is genetic 
background-dependent. This feature renders inbred mouse 
strains a valuable genetic model for quantitative trait loci (QTL) 
studies and the analysis of genetic modifiers co-segregating 
with various disease traits.
10. Insight into additional musculoskeletal complications 
of PSACH-MED revealed for the first time through the in-
depth analysis of mouse models
Several skeletal dysplasias, including PSACH and MED, often 
result from mutations in the extracellular proteins that are 
synthesised by cells of the mesenchymal lineage (39). It is there-
fore not surprising that patients may present with additional 
related musculoskeletal complications (40). Mild PSACH/MED 
patients are sometimes diagnosed with mild myopathy or a 
‘neuromuscular problem of unknown etiology’ prior to the 
confirmation of a chondrodysplasia. Indeed, we have previously 
reported several patients who initially presented with exces-
sive fatigue during walking; difficulty rising from a squatting 
position and mildly elevated serum creatine kinase levels (39). 
These individuals were initially referred to neurological clinics 
for assessment, prior to the diagnosis of a skeletal dysplasia 
following radiographic evaluation. The analysis of muscle 
biopsies often proved inconclusive (40). An in-depth analysis 
of the CompT585M model of mild PSACH/MED (39,41) revealed 
that the mild myopathy observed in patients, and recapitulated 
in this mouse model, was actually the result of an underlying 
tendinopathy that was manifesting primarily at the myotendi-
nous and perimyseal junctions; this finding further correlated 
with joint laxity, which is another prominent clinical feature of 
PSACH and MED patients. Subsequent phenotypic analysis of 
the other two PSACH/MED mouse models (D469del COMP 
and V194D matrilin-3) revealed that both the myopathy and 
underlying tendinopathy were associated with mutant COMP, 
and not mutant matrilin-3, indicating that the neuromuscular 
complications in PSACH and MED are not just a side effect 
of the short limbed dwarfism alone (42). This in-depth pheno-
typic analysis of relevant genetic models of the PSACH-MED 
disease spectrum has yielded important information related 
to the specific site of the musculoskeletal complications and 
their underlying cause; both of which will be value aids for the 
diagnosis and management of these conditions.
11. Strengths and weaknesses of different genetic approaches 
to model skeletal diseases
The various transgenic approaches described in this review 
have both strengths and weaknesses as with all model systems. 
Homologous recombination allows the correct spatial and 
temporal expression of the mutant allele at levels comparable 
to the endogenous allele; however, mice are often required to 
be homozygous for the mutant allele to achieve a recognisable 
and quantifiable phenotype. This is in contrast to individuals 
with autosomal dominant PSACH and MED who only need to 
be heterozygous for the mutation. Posey et al (43) proposed this 
as weakness of the homologous recombination approach and 
suggested that inducible transgenic overexpression is required 
to produce a phenotype in mice that are heterozygous for the 
mutant allele; however, the random integration of multiple 
copies of the mutant transgene into the mouse genome is also 
not representative of the human condition. Furthermore, the 
inducible expression of mutant COMP also has its limitations 
since it is impossible to regulate the amount of dox ingested by 
individual transgenic mice and determining the levels of mutant 
COMP expression in the cartilage of each mouse is not feasible. 
Nevertheless, despite the differences of the two transgenic 
approaches, both mutant mouse lines demonstrated hallmark 
features of PSACH, which included mutant COMP retention, 
increased and dysregulated apoptosis with corresponding areas 
of hypocellularity (15,22,44). Moreover, cell proliferation was 
markedly reduced in both mouse models, which has recently 
been identified as a quintessential feature of growth plate 
dysplasia and reduced bone growth (11).
The use of endogenous Matn3 and Comp promoters by the 
homologus recombination approach (7,15,19) has also allowed 
the in-depth analysis of a range of other musculoskeletal tissues 
that is not possible with Col2a1-driven transgenic overexpres-
sion. These mouse phenotyping studies have confirmed the 
importance of tendinopathy and mild myopathy to the overall 
pathophysiology of PSACH and MED that will ultimately 
provide greater understanding of the clinical presentation of 
these GSDs.
The development and deep phenotyping of ‘ER-stress 
phenocopies’ (30,31) is a novel genotype-independent approach 
for determining the role of ER stress in GSDs. The use of the 
Col2a1 promoter generated a model that exhibited ER stress 
in a broad range of cartilaginous tissues including the growth 
plate and articular cartilages. The resulting phenotype, whilst 
not phenocopying any specific disease, provided a ‘generalised 
chondrodysplasia’ in which to identify fundamental disease 
mechanisms. In contrast, the use of the Col10a1 promoter, which 
specifically targeted expression to hypertrophic chondrocytes, 
accurately phenocopied metaphyseal chondrodysplasias type 
Schmid. In conclusion, this genetic approach demonstrated that 
ER stress can be accurately modelled in either a single cell type 
(or differentiation state) or in an entire tissue and will provide 
a powerful technique for determining the role of ER stress in a 
broad group of inherited connective tissues diseases.
In conclusion, these different genetic mouse models (trans-
genic overexpression expression, knock-in by homologous 
recombination and novel phenocopies) of the PSACH-MED 
phenotypic spectrum have recapitulated key aspects of disease 
pathology and identified new fundamental mechanisms that 
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have both temporal and spatially context within the cartilage 
growth plate. The acquisition of this new knowledge would 
not have been possible through the use of cell culture models, 
which do not recapitulate the dynamic properties of the carti-
lage growth plate.
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